IL291226A - Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept - Google Patents
Methods of treating ocular neovascular diseases using aav2 variants encoding afliberceptInfo
- Publication number
- IL291226A IL291226A IL291226A IL29122622A IL291226A IL 291226 A IL291226 A IL 291226A IL 291226 A IL291226 A IL 291226A IL 29122622 A IL29122622 A IL 29122622A IL 291226 A IL291226 A IL 291226A
- Authority
- IL
- Israel
- Prior art keywords
- methods
- treating ocular
- ocular neovascular
- neovascular diseases
- variants encoding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962899070P | 2019-09-11 | 2019-09-11 | |
US201962913648P | 2019-10-10 | 2019-10-10 | |
PCT/US2019/062066 WO2021050094A1 (en) | 2019-09-11 | 2019-11-18 | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
Publications (1)
Publication Number | Publication Date |
---|---|
IL291226A true IL291226A (en) | 2022-05-01 |
Family
ID=80533961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL291226A IL291226A (en) | 2019-09-11 | 2022-03-09 | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4028037A4 (en) |
JP (1) | JP2023509263A (en) |
KR (1) | KR20220062352A (en) |
CN (1) | CN114390928A (en) |
AU (1) | AU2019465527A1 (en) |
BR (1) | BR112022003206A2 (en) |
CA (1) | CA3147843A1 (en) |
IL (1) | IL291226A (en) |
MX (1) | MX2022002960A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4329721A1 (en) * | 2021-04-27 | 2024-03-06 | Adverum Biotechnologies, Inc. | Methods of treating ocular diseases using aav2 variants encoding aflibercept |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4083203B1 (en) * | 2016-06-16 | 2024-08-07 | Adverum Biotechnologies, Inc. | Compositions and methods for reducing ocular neovascularization |
BR112018076124A2 (en) * | 2016-06-16 | 2019-03-26 | Adverum Biotechnologies Inc | amd treatment using aflibercept aav2 variant |
EP3596213A4 (en) * | 2017-03-17 | 2021-02-17 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression |
-
2019
- 2019-11-18 KR KR1020227011743A patent/KR20220062352A/en unknown
- 2019-11-18 BR BR112022003206A patent/BR112022003206A2/en unknown
- 2019-11-18 CA CA3147843A patent/CA3147843A1/en active Pending
- 2019-11-18 EP EP19944875.4A patent/EP4028037A4/en not_active Withdrawn
- 2019-11-18 JP JP2022515693A patent/JP2023509263A/en active Pending
- 2019-11-18 MX MX2022002960A patent/MX2022002960A/en unknown
- 2019-11-18 CN CN201980100210.9A patent/CN114390928A/en active Pending
- 2019-11-18 AU AU2019465527A patent/AU2019465527A1/en active Pending
-
2022
- 2022-03-09 IL IL291226A patent/IL291226A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2019465527A1 (en) | 2022-03-10 |
EP4028037A1 (en) | 2022-07-20 |
CN114390928A (en) | 2022-04-22 |
JP2023509263A (en) | 2023-03-08 |
KR20220062352A (en) | 2022-05-16 |
EP4028037A4 (en) | 2023-06-28 |
CA3147843A1 (en) | 2021-03-18 |
MX2022002960A (en) | 2022-04-06 |
BR112022003206A2 (en) | 2022-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL291182A (en) | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept | |
IL279919A (en) | Treatment of amd using aav2 variant with aflibercept | |
MX2022012490A (en) | Aav vectors for retinal and cns gene therapy. | |
PH12020500643A1 (en) | Anti-ngf antibodies and methods thereof | |
MX2021011489A (en) | Anti-claudin 18.2 antibody and application thereof. | |
IL288574A (en) | Oligonucleotides and methods of use for treating neurological diseases | |
MX2022005866A (en) | Biparatopic cd73 antibodies. | |
ZA202103035B (en) | Methods of treating graves' ophthalmopathy using anti-fcrn antibodies | |
IL284677A (en) | Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies | |
IL282643A (en) | Combination therapy for treatment of hematological diseases | |
IL290892A (en) | Methods of treating vascular diseases | |
ZA202203776B (en) | Methods of treating epilepsy using the same | |
IL291226A (en) | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept | |
IL290770A (en) | Compounds and methods for treating oxalate-related diseases | |
GB201914034D0 (en) | Treatment of neurological disorders | |
IL287759A (en) | Treatment of headache using anti-cgrp antibodies | |
EP3773603A4 (en) | Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools | |
IL289436A (en) | Methods for treating ocular diseases | |
IL314455A (en) | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept | |
IL290213A (en) | Methods of treating multifocal cancer | |
IL286099A (en) | Methods of treating disease with levoketoconazole | |
IL268111A (en) | Methods of treating pain | |
SG11202112352TA (en) | Expression of antigen-binding proteins in the nervous system | |
IL290351A (en) | Compositions and methods for treating neurological diseases | |
GB201909438D0 (en) | Treatment of diseases |